Prebiotics - Human milk oligosaccharides for infant and adult nutrition

GOS 70% provides HMOs standardized in galactooligosaccharides. These prebiotics contribute to the improvement of infant and adult health through the regulation of the gut microflora, allowing the reinforcement of the immune system and contribute to numerous benefits such as improved digestions, skin health etc.

The power of human milk oligosacharides

Human milk oligosaccharides (HMOs) are complex sugars that are available in human milk. They are the 3rd largest solid component in breast milk after fat and lactose.

More than 150 different oligosaccharides have been identified in human milk and they have an overall prebiotic effect. This means that they pass undigested into the lower part of the gastrointestinal tract where they promote the growth of beneficial microorganisms, such as Bifidobacteria and Lactobacilli.

HMOs are responsible for directly supporting the immune system by: 

Promoting good gut bacteria
Strengthening the gut barrier function
Blocking pathogens

HMOs: galactooligosaccharides are efficient prebiotics

Galactooligosaccharide (GOS): 
Common name for oligosaccharides based on galactose

  • GOS consists of 3-10 molecules of galactose and glucose.
  • These non-digestible prebiotics (non-digestible short-chain soluble fibers) have a prolonged beneficial effect in the large intestine and are effective at a low dose.
  • GOS are resistant to temperature, gastric acids and to hydrolysis by human enzymes.
  • They facilitates the growth of desirable intestinal microflora and can be selectively utilized by beneficial bacteria (Bifidobacteria and Lactobacilli).

 

Characterization of the active compounds

ACTIVE COMPOUNDS

Galactooligosaccharides
GOS > 70%

Formulation

Proven effective from 2000 mg/day

Process of manufacturing of high purity GOS

Manufactured in state-of-the-art facilities

Science supporting GOS 70%

In vitro evaluation of prebiotic activity

The ability of GOS 70% to support the in vitro growth of selected strains of probiotic bacteria has been investigated.
  • GOS 70% selectively promotes the growth of beneficial microbiotypic bacteria (Lactobacilli and Bifidobacteria).
  • The dose-response efficacy of GOS 70% demonstrates a causal relationship.

The symbiotic function of GOS 70% is confirmed.

SD rats were orally fed GOS 70% and/or Bifidobacteria for 30 days. Count of Bifidobacteria in the feces of the rats were performed at the end of the trial to assess of the prebiotic efficacy of GOS 70%.

A larger amount of bacteria and a longer growth period is observed in the GOS 70% and Bifidobacteria group than in the Bifidobacteria group.
Symbiotic function of GOS 70% is confirmed.

A broad spectrum of health benefits

HMOs give newborns multiple layers of protection

These proven benefits support the widely-demonstrated effect of HMOs to formula-fed infants by influencing the establishment of the gut microbiota. 

Protect against 
pathogenic infections

Promote the 
development of intestine

Stimulate the maturation
of the immune system

Help establish 
the gut microbiota

When breastfeeding is unavailable, optimization of infant nutrition is a principal factor required to further support immune development in early life. Research indicates that commercially produced HMOs can mimic some of the health-promoting effects of the HMOs present in human milk.

HMOs rich in galactosyllactose, such as GOS 70%, allow for the creation of formulas that are closer to the profile of natural human milk to provide bottle-fed babies with the benefits of these essential components of breast milk. 

Applications

Commercial name
GOS 70%
Composition
Galactooligosaccharides
ACTIVE COMPOUNDS
GOS > 70%
APPLICATIONS

Dry forms of dietary supplements
Instant powder or orodispersibles
Ready to drink beverages 
Meal substitutes, nutritional bars, confectionery 

OTHERS

Syrup and organic grade available
GRAS, GMO-free, gluten-free

References
K.B. HONG et al.; Food Technol. Biotechnol.; 2016, 54 (2) 156–163 (2016)
K.B. HONG et al.; Asia Pac. J. Clin. Nutr.; 2017;26(4):613-618
K.B. HONG et al.: Int. J. Food Sci. Nutr.; 2015, 66:8, 923-930
K.B. HONG et al.; Korean J. Food Nutr.; 2015, Vol. 28 No. 6, 1026-1032
Y.S. Seo et al.; Curr. Top. Lactic Acid Bac. Probio.; 2016; 4(2):48-53

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Fill form to receive the brochure
Disclaimer

This website is intended to provide information about Fytexia’s ingredients, used in various dietary supplement products around the world. It is intended to provide information to food supplement professionals and is not designed for the general public. As Fytexia’s ingredients are being marketed in a large number of countries, it is the responsibility of each of our customers to ensure that the use of the ingredient and any claim made in the labeling or advertising of the ingredient comply with the applicable rules and regulations.